Integral relationship of some adipocytokineswith glycaemic control and cardiovascular risk in type 2 diabetes mellituswith application of incretin enhancer

Abstract EN

Adipocytokines achieve fundamental physiological targets with respect to energy balance, glucose homeostasis and cardiac performance.

Visfatin, resistin, apelin and leptin are active adipocytokines, however their relations to diabetes mellitus (DM) and cardiovascular functions are poorly elucidated.

The objectives of this study are to clarify the relation of adipocytokines in type 2 DM and cardiovascular risks (hypertension &dyslipidaemia) and their responses after application of incretin enhancer.

Methods: Type 2 DM pa ents and fi een healthy controls were enrolled.

Pa ents were randomized to receive the usual regimen (me ormin 850 mg three mes /d orally) in group I (n=19), incretin (Vildaglip n 50 mg twice/d) in group II (n=17) or the combination of both agents in group III (n= 17) for 14 weeks.

Results: The adiposity related parameters, SBP, DBP, glycaemic control parameters increased significantly (p<0.001) in all diabe c groups relative to the controls in addition to disturbance of lipid profile.

Also, a significant increase in the level of vasfatin, resistin, leptin and apelin in all diabetic patients was observed.

Both incretin enhancer and metformin led to significant improvement in glycaemic parameters (fasting blood glucose and glycosylated haemoglobin), lipid profile (total cholesterol and triglycerides) with more noticeable effects after incretin application.

The addition of incretin enhancer seemed to confer greater benefits in amelioration of Body mass index (BMI), SBP, DBP, fasting insulin level, HDL and the measured adipocytokines levels in group II and III.

However, the advancement get more in the combination group which; suggest the complementary functions of both agents.

Aforementioned changes in adipocytokines of controls were correlated positively with BMI, SBP, DBP, FBG and HBA1c but they non-significantly related to other anthropometrics and laboratory parameters.

At baseline, significant positive correlations between adipocytokines with BMI, FBG and HBA1c in T2 DM pa ents were evident.

These results reflect involvement of adipocytokines in pathophysiology of T2 DM and the associated cardiovascular risks and improvement was proved in BMI, glycaemic control, and cardiovascular complications after application of incretin enhancer nevertheless, the overall clinical monitoring of incretin enhancer must be further assessed in wider scale.